Biotech

All Articles

Actinogen's cortisol blocker falls short stage 2 depression study

.Actinogen Medical's cortisol blocker has actually missed out on the main endpoint of a stage 2 rese...

Bivictrix chooses going personal only method to take ADC into medical clinic

.Antibody-drug conjugates (ADCs) have actually gone to the facility of several a billion-dollar biob...

TPG tops up funds to $580M for financial investments throughout life scientific researches

.Resource manager TPG, which has supported biotechs like Sionna Therapies and Santa Ana Biography, h...

Merck ceases phase 3 TIGIT trial in lung cancer for impossibility

.Merck &amp Co.'s TIGIT program has suffered yet another obstacle. Months after shuttering a phase 3...

After a tough year, Exscientia folds up right into Recursion

.After a year defined by pipe hairstyles, the variation of its own chief executive officer as well a...

Cullinan, after $25M offer, hands back bispecific to Harbour

.Cullinan Therapy was blown away enough along with Harbour BioMed's bispecific immune reactor that i...

A nearer check out Strong Biotech's Ferocious 15

.In this particular full week's incident of "The Leading Line," our team are actually diving in to S...

Lilly experiences phase 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party celebrating the approval of Alzheimer'...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings ...

Lykos will talk to FDA to reevaluate its own selection observing denial of MDMA therapy for post-traumatic stress disorder

.Adhering to an inadequate showing for Lykos Therapies' MDMA prospect for post-traumatic stress diso...